Pharmacological activation of insulin-degrading enzyme improves insulin secretion and glucose tolerance in diet-induced obese mice
- PMID: 37493025
- DOI: 10.1111/dom.15225
Pharmacological activation of insulin-degrading enzyme improves insulin secretion and glucose tolerance in diet-induced obese mice
Abstract
Aim: To investigate the use of synthetic preimplantation factor (sPIF) as a potential therapeutic tool for improving glucose-stimulated insulin secretion (GSIS), glucose tolerance and insulin sensitivity in the setting of diabetes.
Materials and methods: We used a preclinical murine model of type 2 diabetes (T2D) induced by high-fat diet (HFD) feeding for 12 weeks. Saline or sPIF (1 mg/kg/day) was administered to mice by subcutaneously implanted osmotic mini-pumps for 25 days. Glucose tolerance, circulating insulin and C-peptide levels, and GSIS were assessed. In addition, β-cells (Min-6) were used to test the effects of sPIF on GSIS and insulin-degrading enzyme (IDE) activity in vitro. The effect of sPIF on GSIS was also tested in human islets.
Results: GSIS was enhanced 2-fold by sPIF in human islets ex vivo. Furthermore, continuous administration of sPIF to HFD mice increased circulating levels of insulin and improved glucose tolerance, independently of hepatic insulin clearance. Of note, islets isolated from mice treated with sPIF exhibited restored β-cell function. Finally, genetic (shRNA-IDE) or pharmacological (6bK) inactivation of IDE in Min-6 abolished sPIF-mediated effects on GSIS, showing that both the protein and its protease activity are required for its action.
Conclusions: We conclude that sPIF is a promising secretagogue for the treatment of T2D.
Keywords: antidiabetic drug; beta cell function; drug mechanism; insulin secretagogue; insulin secretion.
© 2023 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
References
REFERENCES
-
- Coulam CB, Roussev RG, Thomason EJ, Barnea ER. Preimplantation factor (PIF) predicts subsequent pregnancy loss. Am J Reprod Immunol. 1995;34(2):88-92. doi:10.1111/j.1600-0897.1995.tb00923.x
-
- Barnea ER. Applying embryo-derived immune tolerance to the treatment of immune disorders. Ann N Y Acad Sci. 2007;1110:602-618. doi:10.1196/annals.1423.064
-
- Barnea ER, Kirk D, Paidas MJ. Preimplantation factor (PIF) promoting role in embryo implantation: increases endometrial integrin-alpha2beta3, amphiregulin and epiregulin while reducing betacellulin expression via MAPK in decidua. Reprod Biol Endocrinol. 2012;10:50. doi:10.1186/1477-7827-10-50
-
- Stamatkin CW, Roussev RG, Stout M, et al. PreImplantation factor (PIF) correlates with early mammalian embryo development-bovine and murine models. Reprod Biol Endocrinol. 2011;9:63. doi:10.1186/1477-7827-9-63
-
- Ramu S, Stamatkin C, Timms L, Ruble M, Roussev RG, Barnea ER. PreImplantation factor (PIF) detection in maternal circulation in early pregnancy correlates with live birth (bovine model). Reprod Biol Endocrinol. 2013;11:105. doi:10.1186/1477-7827-11-105
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
